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PURPOSE. To investigate surface expression of CD11b and CD200 on circulating monocytes in
patients with polypoidal choroidal vasculopathy (PCV).
METHODS. This was a prospective case-control study of patients with PCV (n ¼ 27), age-
matched healthy controls (n ¼ 27), and patients with neovascular AMD (n ¼ 49). All
participants underwent a comprehensive ocular examination. Fluorescein and indocyanine
green angiography were performed in patients suspected of neovascular AMD or PCV.
Polypoidal choroidal vasculopathy was angiographically categorized into those with a strong
presence of a branching vascular network (BVN) (type 1) or with a faint/no clear presence of
a BVN (type 2). Fresh venous blood was stained with fluorescent antibodies for flow
cytometric analyses. We compared the percentages of CD11bþ, CD200þ, and
CD11bþCD200þ monocytes between groups of diagnosis and between different angiographic
subtypes of PCV.
RESULTS. Overall, CD11bþ monocytes were both increased in patients with PCV and
neovascular AMD. CD200þ and CD11bþCD200þ monocytes were increased in patients with
neovascular AMD. An age-related increase in CD11bþCD200þ monocytes was absent in
patients with PCV and neovascular AMD. Patients with PCV type 1 had significantly higher
CD11bþ, CD200þ, and CD11bþCD200þ monocytes, whereas patients with PCV type 2 had
levels similar to that in healthy controls.
CONCLUSIONS. We found that PCV is immunologically heterogeneous with significant
differences between angiographic subtypes. Increased CD11bþ and CD200þ monocytes in
those with a strong presence of BVN indicate that BVN development may be associated with
retinal injury and a VEGF-mediated process that is either reflected or propelled by systemic
changes in monocytes.
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Age-related macular degeneration is the most common causeof irreversible vision loss in the elderly of the developed
world.1 The late stage of the disease includes an exudative
phenotype where proliferating choroidal vessels break through
the Bruch’s membrane resulting in hemorrhage and exudate in
the macula, which impairs visual acuity and function.2–4
Although the etiology of neovascular AMD is not fully
understood, growing evidence suggest a key role for chronic
neuroinflammation and microglial activity (resident macro-
phages of the retina) that result in a proinflammatory
environment wherein VEGF secretion is a drive-force for the
choroidal neovascularizations (CNV).5–7 An important differen-
tial diagnosis to neovascular AMD is polypoidal choroidal
vasculopathy (PCV). Polypoidal choroidal vasculopathy was
initially described by Yannuzzi8 in 1982 as a variant of CNV in
the peripapillary area, and since as a clinical entity distinctly
different from neovascular AMD in choroidal originated polyp-
like structures with or without associated branching vascular
network (BVN) typically under the RPE.9–12 Although the
clinical phenotype of PCV is clearly distinct from that of
neovascular AMD, it is still debated whether they share similar
etiology or also differ etiologically.12,13 Tong et al.14 found that
intraocular levels of VEGF may be increased in PCV, but at a
lower level than in neovascular AMD. Genetic studies suggest
similarities and differences in the etiology of PCV and
neovascular AMD.15–17 A recent example is a missense variant
in the FGD6 (FYVE, RhoGEF, and PF domain-containing protein
6) gene that contributes to angiogenesis only in PCV and not in
neovascular AMD.17 However, the amount of studies focusing
on PCV is limited and etiologic aspects as well as similarities
and differences between neovascular AMD and PCV remain to
be understood.
Intravitreal VEGF inhibitors is a part of the treatment of PCV
and VEGF is suspected to play an important role in the
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etiology.12,14 Interestingly, recent reports of treatment out-
comes suggest that PCVs with a strong presence of BVN
respond better to anti-VEGF treatment than PCVs without or
very faint BVNs.18,19 These results suggest that there may be
differences in the etiologic mechanisms between these
angiographic subtypes.20–23 Indeed, genetic studies have found
differences in the genetic background when comparing
patients with these different angiographic subtypes, and
patients with PCV with a strong presence of BVN are more
likely to have a genetic composition similar to that seen in
patients with neovascular AMD.20–22 Polyps without or very
faint BVN on the other hand have been associated with single
nucleotide polymorphisms in the elastin gene suggesting a
different etiologic process than that described for new vessel
formations from the choroid.23
There is a growing interest in the role of circulating
monocytes in AMD.24–28 Macrophages (i.e., monocytes at site
of injury that are differentiated into active phagocytes) possess
both the capability of facilitating clearance of drusen and
fostering an environment that eventually leads to CNV.25,29
Their multifaceted function gives rise to conflicting hypotheses
wherein they are the culprits, the saviors, or both.24,25 Surface
expression of CD11b and CD200 on circulating monocytes
have previously been associated with neovascular AMD.24
CD11b regulates the monocyte adhesion and migration
processes in response to inflammation and CD11bþ monocytes
secrete VEGF at sites of inflammation significantly contributing
to the formation of CNVs.29 Activity of retinal microglia is
regulated through CD200 receptor (CD200R) interaction with
CD200 on neurons and monocytes.30,31 CD200 inhibition leads
to uncontrolled microglia activity and CD200 overexpression is
a regulatory mechanism, whereby neurons and resident or
infiltrating immune cells attenuate microglial activity.24,30–32
These etiologic aspects of circulating monocytes remain
completely unexplored for PCV. Hence, in this study, we
investigated the surface expression of CD11b and CD200 on
circulating monocytes in patients with PCV and compared with
healthy controls and patients with neovascular AMD.
METHODS
This was a prospective case-control study of patients with PCV,
patients with neovascular AMD, and healthy control individu-
als. We explained the nature of the study to all participants and
obtained oral and written consent prior to participation. This
study was approved by the Regional Committee of Ethics in
Research of the Region of Zealand (SJ-379) and followed the
principles stated in the Declaration of Helsinki.
Study Participants
We recruited visitors to the Department of Ophthalmology at
Zealand University Hospital Roskilde between February 2015
and February 2017 for this prospective case-control study.
Patients with neovascular AMD or PCV were recruited
consecutively from our outpatient program. Age-matched
control individuals above 60 years of age were recruited
among healthy visitors, who were primarily a biologically
unrelated relative (e.g., husband or wife) to a recruited patient
with neovascular AMD or PCV. This was an intentional strategy
to match the control group in terms of lifestyles and
exposures. Because no previous studies have investigated
CD11b and CD200 in patients with PCV, power calculations
were based on previous immunologic studies on patients with
neovascular AMD.24 Assuming an alpha level of 0.05, and a
power level of 80%, we calculated that a sample size of 26 in
each group was necessary to obtain sufficient power to detect
differences in CD11bþCD200þ between the three groups of
diagnosis.
Retinal Diagnosis, Clinical Data, and Interviews
Participants were examined using slit-lamp biomicroscopy,
digital fundus photography, and spectral-domain optical
coherence tomography (SD-OCT). Best-corrected visual acuity
(BCVA) was measured in each eye using the Early Treatment of
Diabetic Retinopathy Study (ETDRS) chart.33 Healthy controls
were defined as having less than 10 small drusen (diameter
<63 lm) without pigment abnormalities. Fluorescein and
indocyanine green angiography (ICGA) was used for subtyping
the disease to neovascular AMD or PCV. Neovascular AMD
included cases with fibrovascular pigment epithelium detach-
ments and CNV membranes with subretinal or sub-RPE
hemorrhages or fibrosis. Polypoidal choroidal vasculopathy
was diagnosed in cases with one or more polyps seen in the
early-phase ICGA with a hypofluorescent halo and with or
without BVN. The ICGA video was used to evaluate the
pulsation of polyps. Other PCV characteristics were not
mandatory for the diagnosis, but were used to support the
final diagnosis (fundus examination revealing orange-red focal
subretinal polyp-like structures and retinal OCT showing a
protrusion from the choroid elevating RPE from the Bruch’s
membrane). We further categorized PCVs into subtypes based
on ICGA presence of BVN: type 1, polypoidal lesions with
visible feeder and draining vessels and strong presence of
BVNs; or type 2, polypoidal lesions without clear visible feeder
or draining vessels and without or faint BVNs.18,19,21–23
All participants were interviewed to obtain a list of medical
conditions, and ongoing treatments and medications. Data
were crosschecked with the patient’s electronic patient
record. Smoking habits was categorized in current smokers,
previous smokers (smoked >100 cigarettes during lifetime and
ceased smoking >12 months), or never smokers. Alcohol use
was reported in units/week (1 unit¼ 12-mL ethanol). Physical
activity was assessed using a single question on regular
activity.34,35 Height and weight was measured to calculate
body mass index.
Participant Eligibility
Eligible participants had either healthy retinas, neovascular
AMD in one or both eyes, or PCV in one or both eyes. Because
we measured the systemic immune phenotype of the
individuals, we restricted our study population to individuals
without ongoing immune diseases that can affect our results
and blur our conclusions. Thus, we did not include partici-
pants with a diagnosis of cancer, autoimmune disease, or any
immune, infectious, or inflammatory diseases, or patients who
were receiving chemotherapy or any immune modulating
therapy. We also did not include participants that had received
VEGF inhibitors (anti-VEGF) within the last 4 or 8 weeks for
ranibizumab and aflibercept, respectively, to avoid potential
interaction of systemic antibodies in the following prepara-
tions. Retinal diagnosis including retinal angiography was made
on treatment-na¨ıve eyes, but patients were not recruited on
their first visit as onset of CNV is associated with acute immune
activity.36 Eligible patients were identified and recruited from
follow-up visits. We post-hoc excluded participants with
elevated plasma C-reactive protein levels as this is a sign of
ongoing immune disease.37
Blood Sampling, Preparation, and Flow Cytometry
Venous blood from antecubital veins were sampled in an EDTA-
coated tube for flow cytometric analyses and a lithium heparin
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coated tube for serum CRP measurement. Flow cytometry was
performed within 4 hours after blood sampling. We used an
automated hematology analyzed Sysmex KX-21N (Sysmex
Corporation, Kobe, Japan) to obtain the white blood cell
count, which was used to calculate the volume of blood
needed to obtain 53 105 white blood cells in each test tube.
The red blood cells were lysed using 1% red blood cell lysis
buffer (Nordic Biosite AB, Ta¨by, Sweden) for 10 minutes at
room temperature and in the dark. Cells were washed in an
isotonic buffer (BD FACSFlow; BD Biosciences, Franklin Lakes,
NJ, USA) and centrifuged for 5 minutes at 500g. This process
was repeated three times, after which the cells were
resuspended in the isotonic buffer. We then added the
following monoclonal antibodies: Allophycocyanine-CY7
CD11b, IgG1 j, Clone ICRF44, Cat. No. 557754 (BD
Biosciences); Phycoerythrin-CY7 CD14, IgG2a j, Clone
M5E2, Cat. No. 301814 (BioLegend, San Diego, CA, USA);
and Phycoerythrin CD200, IgG1 j, Clone 325516, Cat. No.
FAB27241P (R&D Systems, Inc., Minneapolis, MN, USA).
Flourochrome-matched negative isotypes were added to a
separately prepared tube: Allophycocyanine-CY7 IgG1 j,
Clone MOPC-21, Cat. No. 400128 (BioLegend); Phycoery-
thrin-CY7 IgG2a j, Clone MOPC-173, Cat. No. 400232
(BioLegend); and Phycoerythrin IgG1 j, Clone MOPC-21, Cat.
No. 555749 (BD Biosciences). Incubation was done at room
temperature in the dark for 20 minutes, after which the cells
were washed and resuspended in the isotonic FACSFlow
buffer. Stained cells were analyzed using flow cytometry (BD
FACSCanto II; BD Biosciences) with a sample size gated for
100,000 singlet leukocytes. Flow data were analyzed using
Kaluza Analysis (Kaluza Analysis v. 1.5.20365.16139; Beckman
Coulter, Inc., Pasadena, CA, USA) by two independent
evaluators (YS and MKN) who were blinded to the conditions
of the participants. We used cell height and area to gate
singlets and size and granularity forward scatter [FSC]/side
scatter [SSC] to gate monocytes, which was then used to
investigate expression of the markers investigated (Fig. 1).
Nonspecific signaling was eliminated using corresponding
negative isotype controls with a threshold of 1%.
Data Analysis and Statistics
All statistics were performed using SPSS 23 (IBM Corporation,
Armonk, NY, USA) and presented using Prism 7 (GraphPad, La
Jolla, CA, USA). Normally distributed continuous data were
presented in mean and SD and compared using parametric
tests; otherwise data were presented in median and inter-
quartile range (IQR) and compared using nonparametric tests.
Categoric variables were presented in numbers and percent-
ages and tested using v2 test, and we used the Fisher’s exact
test when dealing with small categories. We compared the
frequencies of monocytes that were CD11bþ, CD200þ, and
CD11bþCD200þ between the groups. To evaluate the size of
the observed differences between the groups, we calculated
Cohen’s d, which is defined as the ratio between the group
difference and the SD for the data and interpreted following
the suggestions by Cohen and Sawilowksy: <0.2 (negligible/
very small), 0.2 (small), 0.5 (moderate), 0.8 (large), and 1.2
(very large).38,39 We explored immunosenescence (i.e., age-
dependent changes of the immune system) for CD11bþCD200þ
monocytes, for which we previously found an age-related
increment in healthy individuals that was absent in patients
with neovascular AMD.24 Finally, we explored differences in
CD11bþ, CD200þ, and CD11bþCD200þ monocytes among
patients with PCV stratified by their angiographic subtype. P
values below 0.05 were interpret as sign of statistical
significance.
RESULTS
We recruited 31 healthy controls, 27 patients with PCV, and 54
patients with neovascular AMD for this study during the
enrollment period. All participants were Caucasians. Due to
high plasma C-reactive protein levels (>15 mg/L), indicating a
possible ongoing acute immune response, four healthy
controls and five patients with neovascular AMD were
excluded. Thus, our analyses include a total of 103 participants
consisting of 27 healthy controls, 27 patients with PCV, and 49
patients with neovascular AMD. Time from initial retinal
diagnosis for patients with PCV or neovascular AMD to study
recruitment and blood sampling were median 16 (IQR: 4–36)
months and median 18 (9–38) months, respectively, for
patients with PCV and patients with neovascular AMD. Groups
did not differ in in demographics, co-morbidities, or lifestyle
factors (Table 1), but differed significantly in CD11bþ
monocytes (P < 0.001, one-way ANOVA), CD200þ monocytes
(P¼ 0.009, one-way ANOVA), and CD11bþCD200þ monocytes
(P ¼ 0.014, one-way ANOVA).
Patients with PCV had significantly higher CD11bþ mono-
cytes than healthy controls, but CD200þ monocytes did not
differ (Fig. 2). Percentage of CD11bþ monocytes was signifi-
cantly higher than in healthy controls (mean difference: 2.9%,
confidence interval [CI] 95%: 0.8%–5.0%, P ¼ 0.008, indepen-
dent samples t-test). Percentage of CD200þ monocytes did not
differ significantly from healthy controls (mean difference:
0.8%, CI 95%:4.0% to 5.7%, P¼0.740, independent samples t-
test). Percentage of CD11bþCD200þ monocytes also did not
differ significantly from healthy controls (mean difference: 0.
%, CI 95%: 4.2% to 5.9%, P ¼ 0.735, independent samples t-
test). Time from retinal diagnosis to blood sampling (duration
of disease) did not correlate with percentages of CD11bþ
monocytes (q ¼ 0.10, P ¼ 0.604, Spearman’s correlation),
CD200þ monocytes (q ¼ 0.04, P ¼ 0.838, Spearman’s
correlation), or CD11bþCD200þ monocytes (q ¼ 0.05, P ¼
0.796, Spearman’s correlation).
Patients with neovascular AMD had significantly higher
CD11bþ, CD200þ, and CD11bþCD200þ monocytes compared
with healthy controls (Fig. 2). Percentage of CD11bþ mono-
cytes was significantly higher than in healthy controls (mean
difference: 5.2%, CI 95%: 3.1%–7.2%, P < 0.001, independent
samples t-test). Percentage of CD200þ monocytes was signif-
icantly higher than in healthy controls (mean difference: 6.3%,
CI 95%: 2.0%–10.7%, P ¼ 0.005, independent samples t-test).
Percentage of CD11bþCD200þmonocytes was also significantly
higher than in healthy controls (mean difference: 6.4%, CI 95%:
1.7%–11.0%, P¼0.008, independent samples t-test). Time from
retinal diagnosis to blood sampling (duration of disease) did
not correlate with percentages of CD11bþ monocytes (q ¼
0.10, P¼ 0.478, Spearman’s correlation), CD200þ monocytes
( q ¼ 0.08, P ¼ 0.601, Spearman’s correlation), or
CD11bþCD200þ monocytes (q ¼ 0.08, P ¼ 0.578, Spearman’s
correlation).
Patients with PCV differed significantly from patients with
neovascular AMD in CD11bþ, CD200þ, and CD11bþCD200þ
(Fig. 2). Patients with neovascular AMD had a significantly
higher percentage of CD11bþ monocytes (mean difference:
2.3%, CI 95%: 0.9%–3.6%, P ¼ 0.001, independent samples t-
test), CD200þ monocytes (mean difference: 5.5%, CI 95%:
0.3%–10.7%, P ¼ 0.037, independent samples t-test), and
CD11bþCD200þ monocytes (mean difference: 5.5%, CI 95%:
0.1%–11.0%, P ¼ 0.048, independent samples t-test).
Effect sizes of the group differences are shown in Table 2.
The difference in CD11bþ monocytes between patients with
PCV and healthy controls had a moderate size (Cohen’s d: 0.7).
The difference in CD11bþ monocytes between patients with
neovascular AMD and healthy controls had a very large size
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FIGURE 1. Gating strategies to identify CD11bþ, CD200þ, and CD11bþCD200þ monocytes using flow cytometric data in Kaluza software. First, we
identified singlets (A) and then monocytes using forward versus side scatter (B). Then, CD11bþ monocytes were identified (C). The CD200þ
monocytes were less bright, and the percentage of CD200þ monocytes were determined using antibody corresponding negative isotype controls at
1% to distinguish positive cell populations from nonspecific background signals (D). The CD11bþCD200þ co-expressing monocytes was measured
by identifying CD200þ monocytes among CD11bþ monocytes (E). We looked at CD14þ expression on the monocyte population to confirm that the
population investigated was indeed monocytes (F).
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(Cohen’s d: 1.3), whereas for the CD200þ and CD11bþCD200þ
monocytes the sizes were moderate (Cohen’s d: 0.6 and 0.6,
respectively). The differences in CD11bþ, CD200þ, and
CD11bþCD200þ monocytes between patients with PCV and
patients with neovascular AMD were of moderate size (Cohen’s
d: 0.6, 0.5, and 0.5, respectively).
In healthy controls, we found a positive correlation
between age and CD11bþCD200þ monocytes (q ¼ 0.41, P ¼
0.035, Spearman’s correlation) (Fig. 3). This age-related
upregulation of CD11bþCD200þ was absent in patients with
PCV (q ¼ 0.04, P ¼ 0.854, Spearman’s correlation) and in
patients with neovascular AMD (q ¼ 0.03, P ¼ 0.852,
Spearman’s correlation) (Fig. 3), which indicated that
CD11bþCD200þ monocytes in patients with PCV may not be
completely similar to that seen in healthy controls as indicated
by comparisons between groups of diagnosis.
Patients with PCV type 1 (n¼15) differed significantly from
those with type 2 (n ¼ 12): CD11bþ monocytes were
significantly higher (mean difference: 2.85%, CI 95%: 0.9%–
4.8%, P ¼ 0.008, independent samples t-test), CD200þ
monocytes were significantly higher (mean difference 11.1%,
CI 95%: 4.5%–17.6%, P ¼ 0.002, independent samples t-test),
and CD11bþCD200þ monocytes were significantly higher
(mean difference 11.3%, CI 95%: 4.5%–18.0%, P ¼ 0.002,
independent samples t-test). Interestingly, CD11bþ, CD200þ,
and CD11bþCD200þ measurements in patients with PCV type
1 were similar to those in patients with neovascular AMD,
whereas measurements in patients with PCV type 2 were
similar to those in healthy controls (Fig. 4). Patients with PCV
type 1 did not differ from those with type 2 in terms of
demographics, co-morbidities, or lifestyle factors (P > 0.05 for
all comparisons).
DISCUSSION
Angiogenesis and CNV formation depend on monocyte
dynamics.27,28 In this study, we find evidence of altered
phenotype of circulating monocytes in patients with PCV
TABLE 1. Participant Characteristics
Patients With PCV
(n ¼ 27)
Healthy Controls
(n ¼ 27)
Patients With nAMD
(n ¼ 49) P Value
Demographics
Age, y mean (SD) 72.3 (7.6) 74.3 (7.5) 75.7 (7.4) 0.156
Sex, n, females:males 16:11 17:10 24:25 0.448
Co-morbidities
Hypertension, n (%) 11 (41) 10 (37) 25 (51) 0.448
Cardiovascular disease, n (%) 5 (19) 3 (11) 11 (22) 0.494
Hypercholesterolemia, n (%) 9 (33) 9 (33) 12 (25) 0.615
Type 2 diabetes, n (%) 3 (11) 0 (0) 6 (12) 0.201
Lifestyle factors
Smoking, n (%) 0.288
Current 8 (30) 4 (15) 15 (31)
Previous 15 (55) 13 (48) 21 (43)
Never 4 (15) 10 (37) 13 (26)
Alcohol consumption, units, median (IQR) 4 (1–13) 4 (2–7) 3 (1–9) 0.703
Body mass index, mean (SD) 25.4 (4.2) 25.5 (3.4) 26.3 (3.9) 0.537
Physically active, n (%) 15 (56) 17 (63) 25 (51) 0.605
FIGURE 2. CD11bþ, CD200þ, and CD11bþCD200þ monocytes in healthy controls (control), patients with PCV, and patients with neovascular AMD
(nAMD). Whiskers represent mean and 6 standard error. (A) Patients with PCV had more CD11bþmonocytes than controls. Patients with nAMD
had more CD11bþ monocytes than both controls and patients with PCV. (B) Patients with PCV did not differ significantly in CD200þ monocytes
compared with controls. Patients with nAMD had significantly more CD200þ monocytes than controls and patients with PCV. (C) Patients with PCV
did not differ significantly in CD11bþCD200þ monocytes compared with controls. Patients with nAMD had significantly more CD11bþCD200þ
monocytes than controls and patients with PCV.
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depending on angiographic subtype. Strong presence of BVN
was associated with a higher percentage of CD11bþ, CD200þ,
and CD11bþCD200þ monocytes, at a level similar to that seen
in patients with neovascular AMD, which suggests that VEGF
and microglial activity play a role in BVN development. In
contrast, no such changes were found in patients with PCV
without or a very faint BVN, which from an immunologic
perspective were similar to our healthy controls. These
findings suggest that PCV constitute a heterogeneous disease
entity, clinically as well as immunologically, wherein some
aspects are similar to neovascular AMD while others differ.
Crosstalk between systemic circulating immune cells and
the microglia is important for maintaining neuronal
health.25,40 In the aged, anatomic, and physiological changes
of the retina lead to an environment characterized by an
increased need for phagocytosis of cellular by-products and
lipoproteins in the outer retina.41,42 Increased neuronal stress
and injury in the outer retina forces retinal microglia to
migrate from inner to outer retina.43,44 As the resident
phagocytes of the retina, the microglia increases their activity
but may fail to keep up with the increasing phagocytic
demand and retinal stress with age.43,44 This leads to an
environment where circulating monocytes are increasingly
recruited and macrophages accumulate in the retina to keep
up with the need for phagocytosis and increased retinal
stress.26,45 However, this balance in the retina wherein the
monocytes comes in as the saviors is overthrown in the event
of CNV formation in the late stage of AMD. Experimental
models of laser-induced CNV demonstrate that monocytes
infiltrate and determine the aftermath of the injury.27,28
Interestingly, experimental depletion of monocytes attenuates
the size of CNV lesions,27,28 and similar positive correlation
between monocytes and lesion size are seen in patients with
recent onset of neovascular AMD.36 Contributing to a view of
monocytes as the culprits of the story, specific monocytic
phenotypes in the systemic circulation have been associated
with neovascular AMD.24,46,47 Elucidating characteristics of
these monocytic phenotypes is important to understand how
immunologic ageing and dysfunction contributes to the
etiology of AMD.
Ageing leads to an increased systemic expression of IL-10,
which through Signal transducer and activator of transcription
(STAT3)-mediated pathway polarizes macrophages into the
proangiogenic M2 or CD14highCD16þ intermediate pheno-
types.46–48 Blocking IL-10R or STAT3 leads to attenuated CNV
in experimental models confirming the significance of these
age-related monocyte/macrophage changes to the develop-
ment of CNVs.46,47 These proangiogenic CD14highCD16þ
monocytes have a higher expression of CD11b and adhere
up to seven times more efficiently to vascular cell adhesion
molecule 1,49,50 which is upregulated locally in eyes with
neovascular AMD.51 These CD11bþ macrophages are a
significant source of VEGF.29 Interestingly, presence of
complement component 3 regulates CD11b expression and
increased level of complement component 3 fragment C3a is
found in patients with neovascular AMD.52,53 Taken together,
these studies suggest that neovascular AMD is linked to a
combination of immunologic ageing and dysfunction, and
accordingly it is not surprising that our patients with
neovascular AMD have a substantial increase in systemic levels
of CD11bþ monocytes compared with age-matched healthy
controls. In patients with PCV, CD11bþ monocytes were only
moderately increased: however, delving into clinical details
revealed that the level of CD11bþ monocytes did not differ
significantly from the high levels seen in patients with
neovascular AMD when focusing on patients with PCV type
1, whereas the level of CD11bþ monocytes in patients with
PCV type 2 was comparable to healthy controls. Considering
FIGURE 3. Scatterplots to explore relationship between CD11bþCD200þ (y-axis) and increasing age (x-axis) in healthy controls (A), patients with
PCV (B), and patients with neovascular AMD (C) using Spearman’s correlation. In patients with PCV and in patients with neovascular AMD, no
significant relationships were observed. In healthy controls (B), there was a positive correlation between age and CD11bþCD200þ monocytes.
TABLE 2. Size of Differences (Cohen’s d) Between the Groups
CD11bþ Monocytes CD200þ Monocytes CD11bþCD200þ Monocytes
Patients with PCV vs. healthy controls 0.7 (moderate) 0.1 (very small) 0.1 (very small)
Patients with PCV vs. Patients with nAMD 0.6 (moderate) 0.5 (moderate) 0.5 (moderate)
Patients with nAMD vs. healthy controls 1.3 (very large) 0.6 (moderate) 0.6 (moderate)
Cohen’s d is calculated as the ratio between the difference between the groups and the SD for the data. Its interpretation is suggested by Cohen
and Sawilowsky to the following: <0.2 (negligible/very small), 0.2 (small), 0.5 (moderate), 0.8 (large), and 1.2 (very large).
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that CD11bþmacrophages are a strong source of VEGF and that
BVNs consists of newly formed choroidal vessels, results of this
study suggest that VEGF may play a more substantial role for
the disease development in PCV type 1.
Signaling between neurons and monocytes/macrophages
through CD200:CD200R interaction can modulate microglial
and macrophage activity.30–32 Experimental autoimmune
retinitis leads to increased CD200R expression on microglia
and increased CD200 expression on neurons and infiltrating
cells, which suggests that CD200:CD200R interaction is
important in orchestrating a regulated microglial and macro-
phage response.31 It is shown in CD200 knockout mice that
microglia becomes highly present and active in the retina,54
which confirms the regulatory role of CD200:CD200R interac-
tion on the microglia. In this current study, we find that
CD200þ monocytes and CD200þ on CD11bþ monocytes are
increased in patients with neovascular AMD, which is in line
with a previous study.24 Considering the regulatory function of
CD200, upregulation of systemic CD200 in patients with
neovascular AMD may be a regulatory mechanism to dampen
an increased microglial activity due to retinal stress, inflamma-
tion, and CNV. Our study adds to this knowledge as patients
with PCV were found to differ in their CD200þ monocytes
when stratified by angiographic subtype, suggesting strong
presence of BVN may be associated with an increased
microglial activity.
We previously found that ageing was correlated with
CD200þ on CD11bþ monocytes in healthy individuals,24
possibly due to increased microglial activity with age that is
counteracted by systemic regulation. This correlation was
missing in patients with neovascular AMD likely due to
generally upregulated CD200þ on monocytes. In this study,
we also found a correlation between age and CD11þCD200þ
monocytes in healthy controls. Such correlations were lacking
in patients with PCV as well as in patients with neovascular
AMD, possibly reflecting an upregulation due to an increased
microglial activity.
Vascular dysfunction may play a significant role in PCV.
Jones et al.55 investigated previous associations between
HTRA1 and PCV by transgenically expressing human HTRA1
in mice RPE by which the mice developed choroidal-originated
BVN and polypoidal lesions. Zeng et al.56 found that matrix
metalloproteinases 2 and 9, which regulate turnover of
extracellular tissue, were increased in the serum of patients
with PCV compared with early AMD, neovascular AMD, and
healthy controls. These studies indicate that there is a
significant component of vascular dysfunction in PCV. Histo-
pathologic examinations by Nakashizuka et al.57 identified
hyalinization of the choroidal vessels with foamy macrophages
similar to that seen atherosclerosis. Interestingly, binding of
LDL to CD14highCD16þ intermediate proangiogenic circulating
monocytes is a key component in the differentiation toward
foamy macrophages.58
Taken together, we propose that our results and conclu-
sions from previous studies suggest an overall picture of PCV
type 1 as a vascular originated disease propelled by systemic
changes, which manifests as vascular pathologies primarily at
sub-RPE level; whereas neovascular AMD can be considered as
an intraretinal originated disease propelled by systemic
changes, which manifests as vascular and retinal pathologies
at intra- and subretinal level. In contrast, PCV type 2 may be a
vascular originated disease with a limited amount of retinal
damage. Future studies need to confirm and elaborate on these
hypotheses.
It should be noted that our observational study design,
wherein we find associations and correlations does not
necessarily imply causation, which requires experimental
verification. We remain to elucidate whether the observed
changes in the circulatory system reflect a systemic adaptation
to retinal injury and microglial dysfunction, or whether the
changes reflect a fundamental disease in the immune system
that in the event of retinal stress causes vascular growth.
Another limitation is that our study uses a Caucasian
population and its generalizability to non-Caucasian popula-
tions may be complicated by PCV being subject to consider-
able interethnical differences as demonstrated in its
epidemiology, clinical characteristics, and genetic associa-
tions.12,13,59,60
In conclusion, we find that PCV from an immunologic
perspective constitute a heterogeneous disease entity with
important systemic differences between those with and
without BVN. Changes in CD11b and CD200 on monocytes
may reflect that BVN in PCV is a VEGF-mediated process that is
associated with an increased microglial activity or response,
whereas polyps without or very faint BVNs may differ
substantially in their underlying etiology. These findings shed
light on the mechanisms of a poorly understood disease and
suggest that there may not be a simple answer to the question
of whether or not PCV differs etiologically from AMD.
FIGURE 4. CD11bþ, CD200þ, and CD11bþCD200þmonocytes in patients with PCV stratified by angiographic subtype at time of diagnosis. Whiskers
represent mean and 6 standard error. Corresponding mean of healthy controls (dashed line) and mean of patients with nAMD (dotted line) are
included for reference. Polypoidal choroidal vasculopathy type 1 was associated with higher CD11bþ (A), CD200þ (B), and CD11bþCD200þ (C)
monocytes when compared with PCV type 2.
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